Corporate Banner
Satellite Banner
Technology Networks Header
Monday, December 22, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Exiqon Launches Two New Research Use Only Kits
Friday, December 19, 2014
The miRSIGN™ miR-21 Oncogene assay and the miRSIGN™ Colon Cancer assay for PCR analysis of colon cancer samples.

Breaking Barriers in siRNA Delivery
Wednesday, December 17, 2014
Discover a new approach to transfection in the latest DECODED article from IDT.

Bio-Rad Introduces Bio-Plex Pro™ Human Inflammation Panels
Tuesday, December 16, 2014
Superior profiling of cancer, cardiovascular, and other disease biomarkers.

Highly Efficient Neuro Transfection Reagent
Friday, December 12, 2014
DNA-In™ Neuro from AMSBIO offers a cost effective, robust and easy-to-use DNA delivery solution.

Horizon Launches Gene-Engineered Bioproduction Cell Line
Tuesday, December 09, 2014
Precisely engineered cell line will facilitate a new revenue stream and enable faster, more efficient production of therapeutic antibodies.

TGAC Understanding Life on Earth
Thursday, December 04, 2014
The Genome Analysis Centre (TGAC) uses Intel-powered super computers to collect and crunch complex data that is shaping the future of science.

SYGNIS Presents its First Own Product Line: TruePrime™
Tuesday, December 02, 2014
TruePrime™ revolutionizes whole genome and transcriptome amplification.

OSU Launches NGS Cancer Panels Using GO Clinical Workbench
Friday, November 28, 2014
Company’s GO Clinical Workbench™ to enable clinical reporting of mutations detected from NGS.

New Application Note from Malvern Instruments
Thursday, November 27, 2014
Application note shows value of Nanoparticle Tracking Analysis in exosome studies.

<< 1 2 3 4 5 6 7 >>
Showing Results 1 - 10 of 2552
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn